Sana Biotechnology, Inc.

Equities

SANA

US7995661045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
8.26 ^USD	-1.78%		-8.22%	+102.45%

Apr. 09	Certain Restricted Stock Units of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	CI
Apr. 09	Certain Stock Options of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	CI

Sana Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022

March 16, 2023 at 04:15 pm EDT

Sana Biotechnology, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 80.44 million compared to USD 110.73 million a year ago. Basic loss per share from continuing operations was USD 0.42 compared to USD 0.6 a year ago.

Latest news about Sana Biotechnology, Inc.

Certain Restricted Stock Units of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	Apr. 08	CI
Certain Stock Options of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	Apr. 08	CI
Certain Common Stock of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	Apr. 08	CI
JMP Securities Adjusts Sana Biotechnology Price Target to $15 From $8, Maintains Market Outperform Rating	Mar. 01	MT
Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows	Mar. 01	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	Mar. 01	MT
Sana Biotechnology Q4 Non-GAAP Net Loss Narrows; Cash, Cash Equivalents Decline	Feb. 29	MT
Sana Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Sana Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	Feb. 16	MT
Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP	Feb. 13	CI
Sana Biotechnology Insider Bought Shares Worth $9,999,996, According to a Recent SEC Filing	Feb. 12	MT
Sana Biotechnology Insider Bought Shares Worth $9,999,996, According to a Recent SEC Filing	Feb. 12	MT
North American Morning Briefing : Central Bankers -2-	Jan. 17	DJ
HC Wainwright Upgrades Sana Biotechnology to Buy From Neutral, Price Target is $12	Jan. 16	MT
Transcript : Sana Biotechnology, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:45 AM	Jan. 09
Sana Biotechnology Says US FDA Approved Investigational New Drug Application to Launch Clinical Trial for SC262	Jan. 05	MT
Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC262	Jan. 05	CI
Sana Biotechnology Insider Sold Shares Worth $300,098, According to a Recent SEC Filing	Dec. 18	MT
Sana Biotechnology, Inc. Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic Car T Cells in Presentations At the American Society of Hematology Annual Meeting	Dec. 11	CI
Sana Biotechnology Publishes Early Clinical Data Showing That Sc291, A Cd19-Directed Allogeneic Car T Therapy, Evades Immune Detection in Presence of Intact Immune System	Dec. 01	CI
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for Sc291, A Hypoimmune-Modified, Cd19-Directed Allogeneic Car T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and Anca-Associated Vasculitis	Nov. 09	CI
Sana Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
JMP Securities Trims Price Target on Sana Biotechnology to $8 From $9, Maintains Market Outperform Rating	23-10-12	MT
Sana Biotechnology to Cut Spending on Fusogen Platform, Delaying SG299 IND; Workforce Slashed by 29%; Shares Rise	23-10-10	MT

Chart Sana Biotechnology, Inc.

Duration

Period

More charts

Company Profile

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.26 USD

Average target price

11.17 USD

Spread / Average Target

+35.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SANA BIOTECHNOLOGY, INC.	+102.45%	1.82B
IQVIA HOLDINGS INC.	-1.78%	41.36B
LONZA GROUP AG	+45.32%	41.3B
MODERNA, INC.	+4.01%	39.61B
CELLTRION, INC.	-15.14%	25.62B
ICON PUBLIC LIMITED COMPANY	+3.16%	24.09B
ALNYLAM PHARMACEUTICALS, INC.	-24.08%	18.38B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.82B
MEDPACE HOLDINGS, INC.	+24.76%	11.85B
UNITED THERAPEUTICS CORPORATION	+7.01%	11.07B

Other Biotechnology & Medical Research